Trial result ·
Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non-Cystic Fibrosis Bronchiectasis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This analysis modeled how the body handles brensocatib in bronchiectasis. Brensocatib is an oral DPP1 inhibitor. In the ASPEN trial, doses of 10 and 25 mg cut flare-ups compared with placebo. The model was built to support dose choice in adults and adolescents. It pooled data from 11 clinical trials. These had 291 healthy participants and 807 patients.
What they found
The model used 11,643 drug concentration readings. It tested which traits change drug handling. Liver impairment, sex, race and some co-medicines had a statistical effect on clearance. Age and food also had statistical effects. Disease group, kidney impairment and tablet form did not matter statistically. No trait was clinically relevant. The model fit the observed drug levels well in patients.
What it means for patients
The authors say the analysis supports doses of 10 and 25 mg. This applies to patients aged 12 years and older with bronchiectasis. They say no dose change is needed.
Why it is not certain yet
This study shows drug levels, not clinical results. The abstract gives no effect sizes for the traits. Clinical relevance was judged with simulated drug exposure. It was a modeling study.
Source
Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non-Cystic Fibrosis Bronchiectasis.
PubMed · PMID 42712175We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Bronchiectasis publications